Device interoperability and the increased use of continuous glucose monitoring (CGM) dominated much of the discussion at this year's annual American Diabetes Association meeting in San Francisco. Several major CGM players, including Dexcom Inc., Abbott Laboratories Inc., Medtronic PLC and Senseonics Holdings Inc., made big announcements and presented new data, giving conference attendees and the marketplace a lot to talk about.
Market Intel: CGM Market Competition And Device Interoperability Were Hot Topics At ADA2019
Interoperability and the rising use of continuous glucose monitoring is fueling competition among diabetes device-makers and dominated the conversation at the recent annual ADA meeting.

More from Diabetic Care
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.
Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.
More from Device Area
Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.